The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
Publications
Kirby S, Satoskar A, Brodsky S, Pope-Harman A, Nunley D, Hitchcock C, Pelletier R, Ross P, Nadasdy T, Shilo K
Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens.
Diagnostic pathology. 2012;7:25
Sirolimus-induced pneumonitis following liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2007;13(6):853-6
Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.
Chest. 2006;129(6):1718-21
Patterns of pulmonary complications associated with sirolimus.
Respiration; international review of thoracic diseases. 2006;73(3):367-74
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
Transplantation. 2001;72(5):787-90